Bisphosphonates in children with osteogenesis imperfecta may improve bone mineralization but not bone strength. Report of two patients

Journal of Pediatric Endocrinology and Metabolism

Volumn 12, Issue 4, 1999, Pages 555-559

  Roldán, Emilio J A ^a,b   Pasqualini, Titania ^a   Plantalech, Luisa ^a  

^a HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^b NONE   (Argentina)

Author keywords

Bisphosphonate; Bone mass; Osteogenesis imperfecta; Quantitative computerized tomography

Indexed keywords

COLLAGEN TYPE 1; PAMIDRONIC ACID;

ARTICLE; BONE DENSITY; BONE MASS; BONE MINERALIZATION; BONE STRENGTH; CASE REPORT; CHILD; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; GENE MUTATION; HUMAN; MALE; ORAL DRUG ADMINISTRATION; OSTEOGENESIS IMPERFECTA;

EID: 0032791442     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: 10.1515/JPEM.1999.12.4.555     Document Type: Article

References (13)

1. Schiessl H, Ferretti JL, Tysarczyk-Niemeyer G, Willnecker J. Noninvasive bone strength index as analyzed by peripheral quantitative computed tomography (pQCT). In: Schonau E, ed. Pediatric Osteology: New Developments in Diagnostic and Therapy. Amsterdam: Elsevier Science B.V., 1996.
2. Ferretti JL. Noninvasive assessment of bone architecture and biomechanical properties in animals and humans employing pQCT technology. J Jpn Soc Bone Morphom 1997; 7: 115-125.
3. Jamsa T, Jalovaara P, Peng Z, Vaanamen HK, Tuukkanen J. Comparison of three-point bending test and peripheral quantitative computed tomography analysis in the evaluation of the strength of mouse femur and tibia. Bone 1998; 23: 155-161.
4. Pasqualini T, Plantalech L, Roldán E. A phase I/II study of pamidronate (APD) in children with osteogenesis imperfecta (OI). Acta Physiol Pharmacol et Therap Latino Am 1996; 46: 272 (abst).
5. Brumsen C, Hamdy NA, Papapoulos SE. Long-term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis. Medicine 1997; 76: 266-283.
6. Devogelaer JP, Malghem J, Maldague B, Nagant de Deuxchaisnes C. Radiological manifestations of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta. Skeletal Radiol 1987; 16: 360-363.
7. Zanchetta JR, Spivacow RF, Bogado C, Sarli M, Plotkin H, Roldan EJA. Uso prolongado, hasta 6 años, de un amino-bisfosfonato oral en pacientes con osteoporosis establecida. Medicina (Buenos Aires) 1997; 57 (Suppl 1): 37-44.
8. Ferretti JL, Cointry G, Capozza R, Montuori E, Roldán E, Pérez Lloret A. Biomechanical effects of the full range of useful doses of (3-amino-1-hydroxy-propylidene)-1,1-bisphosphonate (APD) on femur diaphysis and cortical bone tissue in rats. Bone Miner 1990; 11: 111-122.
9. Jagger CJ, Chambers TJ, Chow JWM. Stimulation of bone formation by dynamic mechanical loading of rat caudal vertebrae is not suppressed by 3-amino-1-hydroxypropylidene-1-bisphosphonate (AHPrBP). Bone 1995; 16: 309-313.
10. Spivacow FR, Zanchetta JR, Kerzberg EM, Frigeri A, Fiasché R, Roldán EJA. Tolerability of oral pamidronate in elderly patients with osteoporosis and other bone diseases. Curr Ther Res 1996; 57: 123-130.
11. Bembi B, Parma A, Bottega M, Ceschel S, Zanatta M, Martini C, Ciana G. Intravenous pamidronate treatment in osteogenesis imperfecta. J Pediatr 1997; 131: 622-625.
12. Frost HM. Perspectives: bone's mechanical usage windows. Bone Miner 1992; 19: 257-271.
13. Ferretti JL. Biomechanical properties of bone. In: Genant HK, Guglielmi G, Jergas M, eds. Osteoporosis and Bone Densitometry. Berlin: Springer Verlag, 1997; Chap. 8.